Indications
Oxapex is indicated for the treatment of oxygen debt in dogs caused by haemorrhage and haemorrhagic shock and the minimisation of the time to oxygen debt resolution.
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Oxapex
- Group
- Veterinary medicines
- Marketing authorisation holder
- New A Innovation (NL) Limited B.V.
- Status
- Application withdrawn
- EMA product number
- EMEA/V/C/002794
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment